• Pathways, increased use of generics and less expensive alternatives to control costs
• Create a comprehensive program that addresses the 360° view of the patient
• Collaborative efforts between payer and manufacturers to shift reimbursement

• How AstraZeneca and HealthCore are collaborating to build a Real-World Evidence platform and capability
• Importance of observational data, such as electronic medical records, claims information, and patient surveys, in Real-World Evidence studies aimed at determining how to most effectively and economically treat disease
• Examples of Real-World Evidence in practice

• Public and private managed care is demanding improved patient outcomes, but with a more stringent eye on cost of care
• Improving transparency and increased information sharing between payer/pharma can help deliver better health outcomes and reduce costs
• Payers/pharma are beginning to take the steps towards greater collaboration that could realize potential for improving the future of healthcare

• Analysis of the extremely dynamic health environment
• Safe and effective medicines are necessary, but Pharma must develop and deliver compelling value propositions that offer evidence of good economic, clinical and humanistic outcomes.
• Creating value means understanding customer's needs and meeting those with improved information resources and behaviors.

More information coming soon...

• The increasing importance and relevance of Quality Based Payments (QBPs) and pay for performance measures in medication and how this will affect adherence outcomes
• CMS’ Star Ratings program for health plans: detailed insight into the medication safety & adherence measures which impact the overall star rating.
• Key medication metrics you need to know and the crucial like to medication adherence

• Find the right risk management model - high risk/high reward or low risk/low reward
• Examine the role healthcare reform and PPACA has played in managing risk
• Key medication metrics you need to know and the crucial like to medication adherence

• Learn about the various types of ongoing research initiatives from government and private industry
• Understand the key factors involved with real world health outcomes research and pharmacoeconomics
• Develop ways to utilize this information in effective manner for better pharmacy and medical decisions

• Background and update on the biosimilars industry including regulatory changes
• Review of original research conducted with the payer community related to reimbursement and access for biosimilars
• Conclusions including recommendations on how biosimilar companies can improve access and concepts on how biologic innovators can expand their product’s profitability beyond patent expiration